CA3243683A1 - SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUND - Google Patents
SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUNDInfo
- Publication number
- CA3243683A1 CA3243683A1 CA3243683A CA3243683A CA3243683A1 CA 3243683 A1 CA3243683 A1 CA 3243683A1 CA 3243683 A CA3243683 A CA 3243683A CA 3243683 A CA3243683 A CA 3243683A CA 3243683 A1 CA3243683 A1 CA 3243683A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- formula
- compound
- present
- provides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210160862.5 | 2022-02-22 | ||
| CN202210160862 | 2022-02-22 | ||
| PCT/CN2023/077409 WO2023160542A1 (zh) | 2022-02-22 | 2023-02-21 | 二肽基肽酶抑制剂化合物的盐及晶型 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243683A1 true CA3243683A1 (en) | 2025-01-22 |
Family
ID=87764787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243683A Pending CA3243683A1 (en) | 2022-02-22 | 2023-02-21 | SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUND |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250188067A1 (https=) |
| EP (1) | EP4484414A4 (https=) |
| JP (1) | JP2025508792A (https=) |
| KR (1) | KR20240153351A (https=) |
| CN (1) | CN118660873A (https=) |
| AU (1) | AU2023225835A1 (https=) |
| CA (1) | CA3243683A1 (https=) |
| CL (1) | CL2024002490A1 (https=) |
| IL (1) | IL314852A (https=) |
| MX (1) | MX2024010180A (https=) |
| TW (1) | TW202342466A (https=) |
| WO (1) | WO2023160542A1 (https=) |
| ZA (1) | ZA202407225B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314855A (en) * | 2022-02-22 | 2024-10-01 | Haisco Pharmaceuticals Pte Ltd | Preparation method of nitrogen-containing heterocyclic compound |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902181B2 (en) * | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| NO2699580T3 (https=) * | 2014-01-24 | 2018-02-24 | ||
| CN115996923B (zh) * | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
-
2023
- 2023-02-21 JP JP2024549554A patent/JP2025508792A/ja active Pending
- 2023-02-21 KR KR1020247031067A patent/KR20240153351A/ko active Pending
- 2023-02-21 US US18/840,826 patent/US20250188067A1/en active Pending
- 2023-02-21 MX MX2024010180A patent/MX2024010180A/es unknown
- 2023-02-21 AU AU2023225835A patent/AU2023225835A1/en active Pending
- 2023-02-21 CA CA3243683A patent/CA3243683A1/en active Pending
- 2023-02-21 EP EP23759167.2A patent/EP4484414A4/en active Pending
- 2023-02-21 WO PCT/CN2023/077409 patent/WO2023160542A1/zh not_active Ceased
- 2023-02-21 IL IL314852A patent/IL314852A/en unknown
- 2023-02-21 CN CN202380015239.3A patent/CN118660873A/zh active Pending
- 2023-02-22 TW TW112106411A patent/TW202342466A/zh unknown
-
2024
- 2024-08-20 CL CL2024002490A patent/CL2024002490A1/es unknown
- 2024-09-20 ZA ZA2024/07225A patent/ZA202407225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4484414A4 (en) | 2026-01-28 |
| WO2023160542A1 (zh) | 2023-08-31 |
| AU2023225835A1 (en) | 2024-10-03 |
| ZA202407225B (en) | 2025-12-17 |
| CN118660873A (zh) | 2024-09-17 |
| EP4484414A1 (en) | 2025-01-01 |
| CL2024002490A1 (es) | 2024-12-13 |
| MX2024010180A (es) | 2024-08-27 |
| JP2025508792A (ja) | 2025-04-10 |
| TW202342466A (zh) | 2023-11-01 |
| IL314852A (en) | 2024-10-01 |
| US20250188067A1 (en) | 2025-06-12 |
| KR20240153351A (ko) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4484424A1 (en) | Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor | |
| US20250188067A1 (en) | Salt and crystal form of dipeptidyl peptidase inhibitor compound | |
| JP2023024729A (ja) | ヤヌスキナーゼ阻害剤の結晶形 | |
| WO2016178416A1 (ja) | ウラシル化合物の新規結晶 | |
| AU2018251119A1 (en) | Opioid receptor (MOR) agonist salt, fumarate salt I crystal form thereof and preparation method thereof | |
| JP2021073256A (ja) | セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）の阻害剤の医薬的塩形態 | |
| KR101557832B1 (ko) | (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 | |
| CA2413087C (en) | Suplatast tosilate crystals | |
| CN116041324B (zh) | 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途 | |
| JP7187733B2 (ja) | オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶 | |
| US11136332B2 (en) | Morphic forms of marizomib and uses thereof | |
| EA053095B1 (ru) | Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы | |
| WO2007080362A1 (en) | Pharmaceutically acceptable co-crystalline forms of sildenafil | |
| JP5265876B2 (ja) | アンドラストの新規で安定な結晶構造体 | |
| US20190062307A1 (en) | Deuterium-substituted quinoline derivatives | |
| CN112174895B (zh) | 一种雄性激素受体抑制剂的晶型及其制备方法 | |
| EA051477B1 (ru) | Полиморф ингибитора дипептидилпептидазы 1, способ его получения и применение | |
| WO2026017797A1 (en) | Crystalline forms | |
| CN116396305A (zh) | 一种稠环衍生物的晶型、其制备方法及其应用 | |
| AU2022412842A1 (en) | Novel acid addition salt and crystalline form of (2r,3s)-2-(3-(4,5-dichloro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol | |
| JP2007332032A (ja) | 医薬結晶化合物 | |
| HK1249906B (en) | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao) | |
| HK1109629A (en) | A new crystalline and stable form of andolast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240802 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240805 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240805 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241003 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250122 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250128 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |